» Articles » PMID: 34358082

Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma

Overview
Publisher MDPI
Specialty Chemistry
Date 2021 Aug 6
PMID 34358082
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) has emerged as one of the most lethal cancers worldwide because of its high refractoriness and multi-drug resistance to existing chemotherapies, which leads to poor patient survival. Novel pharmacological strategies to tackle HCC are based on oral multi-kinase inhibitors like sorafenib; however, the clinical use of the drug is restricted due to the limited survival rate and significant side effects, suggesting the existence of a primary or/and acquired drug-resistance mechanism. Because of this hurdle, HCC patients are forced through incomplete therapy. Although multiple approaches have been employed in parallel to overcome multidrug resistance (MDR), the results are varying with insignificant outcomes. In the past decade, cancer immunotherapy has emerged as a breakthrough approach and has played a critical role in HCC treatment. The liver is the main immune organ of the lymphatic system. Researchers utilize immunotherapy because immune evasion is considered a major reason for rapid HCC progression. Moreover, the immune response can be augmented and sustained, thus preventing cancer relapse over the post-treatment period. In this review, we provide detailed insights into the immunotherapeutic approaches to combat MDR by focusing on HCC, together with challenges in clinical translation.

Citing Articles

Decoding Immune Signature to Detect the Risk for Early-Stage HCC Recurrence.

Devan A, Nair B, Aryan M, Liju V, Koshy J, Mathew B Cancers (Basel). 2023; 15(10).

PMID: 37345066 PMC: 10216348. DOI: 10.3390/cancers15102729.


Translational Phytomedicines against Cancer: Promise and Hurdles.

Devan A, Nair B, Nath L Adv Pharm Bull. 2023; 13(2):210-215.

PMID: 37342376 PMC: 10278225. DOI: 10.34172/apb.2023.023.


Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma.

Devan A, Pavithran K, Nair B, Murali M, Nath L World J Gastroenterol. 2022; 28(36):5250-5264.

PMID: 36185626 PMC: 9521521. DOI: 10.3748/wjg.v28.i36.5250.


Design and In Vitro Evaluation of Novel Cationic Lipids for siRNA Delivery in Breast Cancer Cell Lines.

Vaidya S, Jeengar M, Wadaan M, Mahboob S, Kumar P, Reece L Evid Based Complement Alternat Med. 2022; 2022:9231641.

PMID: 35707479 PMC: 9192290. DOI: 10.1155/2022/9231641.


Blockade of Uttroside B-Induced Autophagic Pro-Survival Signals Augments Its Chemotherapeutic Efficacy Against Hepatocellular Carcinoma.

Nath L, Swetha M, Vijayakurup V, Thangarasu A, Haritha N, Shabna A Front Oncol. 2022; 12:812598.

PMID: 35211405 PMC: 8861526. DOI: 10.3389/fonc.2022.812598.

References
1.
Peterson B, Tan K, Osa-Andrews B, Iram S . High-content screening of clinically tested anticancer drugs identifies novel inhibitors of human MRP1 (ABCC1). Pharmacol Res. 2017; 119:313-326. DOI: 10.1016/j.phrs.2017.02.024. View

2.
Pratama M, Pascut D, Massi M, Tiribelli C . The role of microRNA in the resistance to treatment of hepatocellular carcinoma. Ann Transl Med. 2019; 7(20):577. PMC: 6861820. DOI: 10.21037/atm.2019.09.142. View

3.
Caumanns J, Berns K, Wisman G, Fehrmann R, Tomar T, Klip H . Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. Clin Cancer Res. 2018; 24(16):3928-3940. PMC: 6098697. DOI: 10.1158/1078-0432.CCR-17-3060. View

4.
Chraa D, Naim A, Olive D, Badou A . T lymphocyte subsets in cancer immunity: Friends or foes. J Leukoc Biol. 2018; 105(2):243-255. DOI: 10.1002/JLB.MR0318-097R. View

5.
Liu J, Liu Y, Meng L, Liu K, Ji B . Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep. 2017; 38(2):899-907. PMC: 5561980. DOI: 10.3892/or.2017.5722. View